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Abstract: Nurse practitioners (NPs) have a unique opportunity as frontline caregivers and 
patient educators to recognize, assess, and effectively treat the widespread problem of uncon-
trolled asthma. This review provides a perspective on the role of the NP in implementing the 
revised National Asthma Education and Prevention Program (NAEPP) Guidelines put forth by 
the National Heart, Lung, and Blood Institute, thereby helping patients achieve and maintain 
asthma control. A literature search of PubMed was performed using the terms asthma, nurse 
practitioner, asthma control, burden, impact, morbidity, mortality, productivity, quality of life, 
uncontrolled asthma, NAEPP guidelines, assessment, pharmacotherapy, safety. Despite the 
increased morbidity and mortality and impaired quality of life attributable to uncontrolled 
asthma, the 2007 NAEPP asthma guidelines are greatly underused. NPs have an opportunity 
to identify patients at risk and provide enhanced care and education for asthma control. Often, 
NPs can prescribe medication for and manage these patients, but it is necessary to be able to 
discern which patients require referral to a specialist.
Keywords: asthma control, asthma medications, education, NAEPP guidelines, nurse 
  practitioner, referral
Introduction
Asthma is a global health problem, burdening patients, families, health care   systems, 
and governments.1 Despite the availability of several treatments and disease 
  management guidelines, many patients have asthma that remains uncontrolled or 
not adequately controlled.2,3 In a study by Sullivan et al, few patients with severe 
or difficult-to-treat asthma achieved asthma control during a 2-year period: 83% of 
patients had uncontrolled asthma, 16% had asthma inconsistently controlled, and only 
1.3% had controlled asthma during all assessment periods.4
The review
This article is intended to increase nurse practitioners’ (NPs) awareness of the preva-
lence of uncontrolled asthma and provide key information and tools for assessing and 
maintaining asthma control.
Source materials
The 2007 National Asthma Education Prevention Plan (NAEPP) guideline recom-
mendations for asthma assessment and management, including referral of patients with 
difficult-to-treat asthma to an asthma specialist, serve as the primary source material. 
In addition, selected references related to asthma epidemiology and pathophysiology Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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were obtained from a literature search of PubMed using the 
terms: asthma, nurse practitioner, asthma control, burden, 
impact, morbidity, mortality, productivity, quality of life, 
uncontrolled asthma, NAEPP guidelines, assessment, phar-
macotherapy, safety.
Benefits of controlled asthma
Uncontrolled asthma can lead to increased morbidity and 
mortality, impaired quality of life (QOL), and increased 
absenteeism from work and school.5 Increased health care 
costs including both direct and indirect costs of asthma man-
agement are another consequence of uncontrolled asthma,5 
thus underscoring the need for improved symptom control 
among people with asthma.
Controlled asthma has been shown to reduce morbidity, 
improve QOL, increase productivity, and improve health 
outcomes.4,6 In addition, data from the 2006 US National 
Health and Wellness Survey showed that patients with con-
trolled asthma reported decreased medical resource   utilization 
(fewer emergency department visits, hospitalizations, and 
unscheduled clinic visits) compared with patients who had 
uncontrolled asthma.6 The improved health   outcomes asso-
ciated with asthma control indicate that management with 
therapies that optimize asthma control may reduce direct and 
indirect costs of treatment.4
2007 NAEPP asthma guidelines 
(EPR-3) for asthma control
In 2007, the NAEPP issued the third Expert Panel Report 
(EPR-3), a set of evidence-based clinical practice guide-
lines that incorporate best practices to help people with 
asthma control their disease, and provide guidance to 
clinicians in asthma management.7 Major changes from 
the previous set of guidelines include a new focus on 
monitoring asthma control as the goal for asthma therapy 
and on distinguishing between classifying asthma sever-
ity (defined as the intensity of the disease process) and 
monitoring asthma control (defined as the degree to which 
therapeutic interventions minimize the manifestations of 
asthma or meet the goals of therapy).7 These guidelines 
emphasize that the functions of assessment and monitor-
ing are closely linked to the concepts of severity, control, 
and the patient’s responsiveness to treatment, and that 
both severity and control include the domains of current 
impairment and future risk.7 Impairment is described as 
the frequency and intensity of symptoms or functional 
limitations the patient encounters, and risk is defined 
as the possibility of asthma exacerbations, progressive 
decline in lung   function (or, for children, lung growth), or 
adverse effects related to asthma medications.7 Including 
the domains of current impairment and future risk reflects 
the multifaceted nature of asthma, and the need to consider 
separately the impact of asthma QOL, functional capacity, 
and the risk of future adverse events (AEs).7
The EPR-3 provides specific guidance for periodic 
assessment and ongoing monitoring to determine whether 
the goals of asthma therapy are being achieved and asthma is 
being controlled.7 Figure 1 shows the recommended methods 
for classifying asthma severity; Figure 2 shows the recom-
mended methods for classifying asthma control. Asthma 
severity should be assessed to provide a basis for initial 
treatment; once treatment is initiated, the focus of clinical 
management becomes the assessment of asthma control to 
determine whether therapy should be maintained or adjusted. 
Periodic assessment of asthma control is recommended at 
1- to 6-month intervals and should include measuring signs 
and symptoms of asthma, pulmonary function, history of 
asthma exacerbations, and aspects of pharmacotherapy.7 
The level of asthma control is the degree to which both 
domains of the manifestations of asthma – impairment and 
risk – are minimized by therapeutic intervention.7 The cur-
rent guidelines classify levels of asthma control using the 
following categories: well controlled, not well controlled, 
or very poorly controlled.7
To achieve and maintain control of asthma, the guidelines 
recommend a stepwise approach that utilizes 6 steps.7 This 
approach is outlined in Figure 3.
The importance of adhering to guidelines in order to 
meet and maintain goals of asthma control was demon-
strated in a large, randomized, double-blind, interven-
tion trial in which significant reductions in the rate of 
severe exacerbations and improvements in QOL resulted 
when asthma control as defined by the Global Initia-
tive for Asthma/National   Institutes of Health (NIH) was 
achieved.8
Results from an intervention-based asthma assessment 
and management program suggested that implementing 
asthma guidelines at the point of care may lead to improved 
asthma control.9 Nevertheless, there are known gaps 
between the development and distribution of guidelines and 
their implementation; in fact, it often takes many years for 
guidelines to be incorporated into clinical practice.10 The 
NAEPP treatment guidelines have had limited effects on 
physician behavior, thus contributing to their underutiliza-
tion in   practice.11 Possible barriers to guideline use include Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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In 2–6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly.
and consider short course of oral systemic corticosteroids
Step 4 or 5 Step 3 Step 2 Step 1 Recommended Step
for Initiating Treatment
(See “Stepwise Approach for Managing Asthma”
for treatment steps.)
Consider severity and interval since last exacerbation.
Frequency and severity may fluctuate over time for patients in any severity category.
Relative annual risk of exacerbations may be related to FEV1.
Extremely limited Some limitation Minor limitation None Interference with normal 
activity
Often 7×/week ≤2×/month
Persistent
Classification of asthma severity (≥12 years of age)
•F EV1 <60% predicted
•F EV1/FVC reduced 
>5%
Several times per day
Throughout the day
Severe
≥2/year (see note) 0–1/year (see note)
Exacerbations requiring 
oral systemic 
corticosteroids
Risk
•F EV1 >60% but <80% 
predicted
•F EV1/FVC reduced 5%
•F EV1 >80% predicted
•F EV1/FVC normal
•N ormal FEV1 between 
exacerbations
•F EV1 >80% predicted
•F EV1/FVC normal
Lung function
Daily >2 days/week but not daily, 
and not more than 1× on 
any day
≤2 days/week Short-acting β2-agonist use 
for symptom control (not 
prevention of EIB)
Moderate Mild Intermittent
Components of severity
>1×/week but not nightly 3–4×/month Nighttime awakenings
Impairment
Normal FEV1/FVC:
8–19 yr 85%
20–39 yr 80%
40–59 yr 75%
60–80 yr 70%
Daily >2 days/week but not daily ≤2 days/week Symptoms
Figure 1 Methods of classifying asthma severity and initiating treatment in patients 12 years of age and older.
Notes: Level of severity is determined by assessment of both impairment and risk. Assess impairment domain by patient’s/caregiver’s recall of previous 2–4 weeks and 
spirometry. Assign severity to the most severe category in which any feature occurs. At present, there are inadequate data to correspond frequencies of exacerbations with 
different levels of asthma severity. in general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or iCU admission) indicate 
greater underlying disease severity. For treatment purposes, patients who had $2 exacerbations requiring oral systemic corticosteroids in the past year may be considered 
the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma. Reproduced from the National Heart Lung and 
Blood institute.7
Abbreviations: eiB, exercise-induced bronchospasm; Fev1, forced expiratory volume in 1 second; FvC, forced vital capacity; iCU, intensive care unit.
patient- and environmental-related factors such as patient 
resistance to guidelines or the need for additional office 
and counseling resources. In addition, if guidelines are 
inconvenient, cumbersome, or confusing, they may not be 
incorporated into clinical practice.12–15
The advantages of NPs as educators 
and primary providers
NPs have a unique opportunity to identify patients at risk, 
and provide enhanced care and education for asthma control, 
because they are at the front line of patient care.16 Both 
prospective and “real-world” observational studies have 
shown that NPs are key primary providers and educators 
in the management of chronic   diseases, including asthma, 
acting as partners with physicians in providing complemen-
tary, collaborative, chronic disease management associated 
with favorable patient outcomes.17,18 A cross-sectional sur-
vey showed that nearly 50% of patients preferred NPs to 
general practitioners (or had no preference) for educational 
aspects of care, and were more satisfied with the NP for 
those aspects of care related to support of patients and their 
families.19   Conversely, patients preferred medical aspects 
of care to be managed by the physician.19 A qualitative 
interview study showed that the input of specialist nurses 
helped practice nurses to identify, follow-up, and audit the 
care of high-risk asthma patients.20 In the inpatient setting, 
pediatric NPs have been shown to be effective care managers 
and educators.21 These findings underscore the beneficial 
skill mix provided when NPs and physicians work together 
for their patients, showing that this approach may meet 
the needs of patients more effectively than care from the 
physician alone.
A sound partnership between the NP and patient is 
critical for consistent asthma control.7 The NP can develop 
an active partnership with the patient by establishing open 
communication; identifying and addressing patient and 
  family concerns about asthma and asthma treatment; devel-
oping treatment goals; selecting medications collaboratively 
with the   physician, patient, and family; and encouraging 
  self-monitoring and treatment.7 Self-management educa-
tion, in particular, has been shown to improve outcomes 
(eg, reduced the number of emergency department visits, 
hospitalizations, limitations on activities, improved health 
status, QOL, and perceived control of asthma).7 A hospital-
based study showed that asthma consultations with specialist 
asthma nurses improved patient self-management behavior 
and thereby reduced symptoms, improved lung function, and 
decreased work days lost.22Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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Assessment of asthma control
A key role of the NP is evaluating the patient’s asthma   control. 
This ongoing process involves both clinical and patient 
self-assessment (see Figure 4 for a sample patient’s assess-
ment sheet). The primary methods for clinical   monitoring 
and control of asthma in clinical practice are assessment of 
symptoms; use of short-acting β2-agonists for quick relief 
of symptoms; and limitations on normal activities due to 
asthma, pulmonary function, and exacerbations.7 In   addition, 
the EPR-3 recommends that patients be encouraged to use 
  self-assessment tools.7 Obtaining the perspective of the patient 
and/or the patient’s family on whether the patient’s asthma is 
well controlled can add to the clinical evaluation. The “rule 
of 2s”, which classifies asthma control based on frequency 
of asthma symptoms, nighttime awakenings, and use of 
short-acting beta2 agonists (SABAs) for symptom control, is 
a helpful interpretation of the patient’s input. These and other 
components of asthma control are described in Table 1.7
 Assessing asthma control can help the NP evaluate 
both current health status and identify patients at risk for 
future health impairment.23 Some of the validated instru-
ments available for assessing asthma control include the 
Asthma Control Questionnaire (ACQ), the Asthma Therapy 
Assessment Questionnaire (ATAQ), and the Asthma Con-
trol Test (ACT) (Table 2).7 An official statement by the 
American Thoracic Society/European Respiratory Society 
acknowledged that these tools are easy to administer and 
interpret but do not provide full information on a patient’s 
current clinical state and should only be used as a part of a 
full assessment.24
ACQ
The ACQ is a questionnaire developed to meet the criteria 
set forth by international guidelines (ie, those issued by the 
Global Initiative for Asthma and the British Thoracic   Society) 
for optimizing asthma control.25 This tool measures the 
adequacy of and change in asthma control (spontaneous or 
as a result of treatment).26 Consisting of 7 equally weighted 
items, the ACQ scores the patient-reported frequency 
of nighttime awakenings, symptoms on waking, activity 
Medication site effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does 
not correlate to specific levels of control but should be considered in the overall assessment of risk.
Treatment-related adverse 
effects
Evaluation requires long-term follow-up care. Progressive loss of lung 
function
Consider severity and interval since last exacerbation
•C onsider short course of oral 
systemic corticosteroids
•S tep up 1–2 steps
•R eevaluate in 2 weeks
•F or side effects, consider 
alternative treatment options
Extremely limited Some limitation None Interference with normal 
activity
•S tep up 1 step
•R eevaluate in 2–6 weeks
•F or side effects, consider 
alternative treatment options
•M aintain current step
•R egular follow-up at every 1–6 
months to maintain control
•C onsider step-down if well controlled 
for at least 3 months
Recommended Action for Treatment
(See “Stepwise Approach for Managing 
Asthma”f or treatment steps.)
<60% predicted/personal best 60%-80% predicted/personal best >80% predicted/personal best FEV1 or peak flow
≤2×/month
Classification of asthma control (≥12 years of age)
≥2/year (see note) 0–1/year Exacerbations requiring oral 
systemic corticosteroids
Risk
3–4
NA
≤15
1–2
≥1.5
16–19
0
≤0.75*
≥20
Validated questionnaires
ATAQ
ACQ
ACT
Several times per day >2 days/week ≤2 days/week Short-acting β2-agonist use 
for symptom control (not 
prevention of EIB)
Very poorly controlled Not well controlled Well controlled
Components of control
≥4×/week  1–3×/week Nighttime awakenings
Impairment
Throughout the day >2 days/week  ≤2 days/week Symptoms
Figure 2 Methods of classifying asthma control and adjusting treatment in patients 12 years of age and older.
Notes: *ACQ values of 0.76 to 1.4 are indeterminate for well-controlled asthma. Minimal important Difference: 1.0 for the ATAQ; 0.5 for the ACQ; not determined for the 
ACT. The level of control is based on the most severe impairment or risk category. Assess impairment domain by patient’s recall of previous 2–4 weeks and by spirometry 
or peak flow measures. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient’s asthma is better or worse since 
the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. in general, more frequent and intense 
exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or iCU admission) indicate poorer disease control. For treatment purposes, patients who had $2 
exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not-well-controlled asthma, even in the absence of 
impairment levels consistent with not-well-controlled asthma. Before step-up in therapy: (1) Review adherence to medication, inhaler technique, environmental control, and 
comorbid conditions. (2) if an alternative treatment option was used in a step, discontinue and use the preferred treatment for that step. Reproduced from the National 
Heart Lung and Blood institute.7
Abbreviations: Fev1, forced expiratory volume in 1 second; eiB, exercise-induced bronchospasm; N/A, not applicable; ATAQ, Asthma Therapy Assessment Questionnaire; 
ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test.Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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Persistent asthma: Daily medication
Consult with asthma specialist if step 4 care or higher is required.
Consider consultation at step 3.
Intermittent 
asthma
Step 1
Preferred:
SABA PRN
Step 2
Preferred:
Low-dose ICS
Alternative:
Cromolyn, 
LTRA, 
Nedocromil, or 
Theophylline
Step 3
Preferred:
Low-dose ICS 
+ LABA
OR
Medium-dose 
ICS
Alternative:
Low-dose ICS 
+ either LTRA, 
Theophylline, 
or Zileuton
Step 4
Preferred:
Medium-dose 
ICS + LABA
Alternative:
Medium-dose 
ICS + either 
LTRA, 
Theophylline, 
or Zileuton
Step 6
Preferred:
High-dose ICS 
+ LABA + oral  
corticosteroid
AND
Consider 
Omalizumab 
for patients 
who have 
allergies
Step 5
Preferred:
High-dose ICS 
+ LABA
AND
Consider 
Omalizumab 
for patients 
who have 
allergies
Step up if 
needed
(first, check 
adherence, 
environmental 
control, and 
comorbid 
conditions)
Step down if 
possible 
(and asthma 
is well controlled 
at least 3 
months)
Assess
control
Each step: patient education, environmental control, and management of comorbidities.
Steps 2–4: Consider subcutaneous allergen immunotherapy for patients who have allergic asthma (see notes).
Quick-relief medication for all patients
• SABA as needed for symptoms. Intensity of treatment depends on severity of symptoms: up to 3 treatments
at 20-minute intervals as needed. Short course of oral systemic corticosteroids may be needed.
• Use of SABA >2 days a week for symptom relief (not prevention of EIB) generally indicates inadequate control
and the need to step up treatment.
Figure 3 Stepwise approach for managing asthma in patients aged $12 years.
Note: Alphabetical order is used when more than one treatment option is listed within either preferred or alternative therapy. Reproduced from the National Heart Lung 
and Blood institute.7
Abbreviations: iCS, inhaled corticosteroid; LABA, long-acting inhaled beta2-agonist; LTRA, leukotriene receptor antagonist; SABA, inhaled short-acting beta2-agonist.
  limitation, shortness of breath, wheeze, rescue SABA use 
during the prior week, and clinic-evaluation forced expiratory 
volume in 1 second % predicted prebronchodilator.25 The total 
ACQ score is the mean of the 7 items, which ranges from 
0 (totally controlled) to 6 (severely uncontrolled).25
ATAQ
The ATAQ is a self-administered questionnaire that assesses 
asthma control with questions about self-perceived asthma 
symptom control; missed work, school, or daily activities; 
nighttime awakenings due to symptoms; and use of quick-
relief inhaler medication.27 The number of control problems 
is summed from all questions for a total score in which 0 = no 
control issues present and 4 = all 4 control issues present.27 
This index provides a simple way to identify patients poten-
tially at risk of poor asthma control, and can detect specific 
problem areas (eg, overuse of reliever medications, nocturnal 
wakening, and interference with activities) that can serve as 
a basis for discussion with the patient.28
ACT
The ACT is a 5-item questionnaire, administered in the doc-
tor’s office, which evaluates patient-reported shortness of 
breath, asthma control, use of rescue medication, productivity 
at work or school, and nighttime awakenings due to asthma 
symptoms.29 Although ACT could be used for many different 
applications (eg, an investigator selecting patients for clini-
cal trials or a clinician involved in a disease management 
program), it does not provide a particular score level as a 
cut point; rather, the designers of this instrument encour-
age health care providers to select the most appropriate cut 
point for their patient’s situation.29 The combination of the 
ACT and lung function testing has been shown to be a more 
useful strategy for predicting future exacerbation of asthma 
compared with either method used alone.30
The asthma action plan
An asthma action plan – a written, individualized set of 
instructions for daily management (including actions to Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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Table 1 Classification of well-controlled asthma
Components of control Value
The “Rule of 2s”
  Asthma symptoms #2 days per week
  Nighttime awakenings #2 times per month
    SABA use for symptom control  
(not prevention of eiB)
#2 days per week
Other measurements
  interference with normal activity None
  Fev1 or PeF .80% predicted/personal best
Abbreviations: eiB, exercise-induced bronchoconstriction; Fev1, forced expiratory 
volume in 1 second; PEF, peak expiratory flow; SABA, short-acting β2-agonist.
Note: Reproduced from the National Heart Lung and Blood institute.7
Name:   D ate: 
Your asthma control 
How many days in the past week have you had chest tightness, cough, shortness of breath, or wheezing
(whistling in your chest)? 
01234567
How many nights in the past week have you had chest tightness, cough, shortness of breath, or wheezing
(whistling in your chest)? 
Do you perform peak flow readings at home? _      yes          no 
If yes, did you bring your peak flowchart?         yes          no 
How many days in the past week has asthma restricted your physical activity? 
Have you had any asthma attacks since your last visit?         yes          no 
Have you had any unscheduled visits to a doctor, including to the emergency department, since your last visit?
        yes          no 
How well controlled is your asthma, in your opinion?
somewhat controlled
not well controlled
Average number of puffs per day of quick-relief 
medication (short-acting beta2-agonist)
Taking your medicine
What problems have you had taking your medicine or following your asthma action plan? 
Please ask the doctor or nurse to review how you take your medicine. 
Your questions 
What questions or concerns would you like to discuss with the doctor? 
How satisfied are you with your asthma care?
These questions are examples and do not represent a standardized assessment instrument.
01234567
01234567
very well controlled 
somewhat satisfied
not satisfied
very satisfied
Figure 4 Sample patient self-assessment sheet for follow-up visits.
manage worsening asthma and signs and symptoms that 
indicate the need for immediate medical care) – is a tool 
NPs can use to help optimize a patient’s asthma control. The 
NAEPP recommends that all asthma patients be provided 
with such a plan.7 The use of an action plan as part of the 
patient’s asthma self-management has been shown to reduce 
the number of missed school and work days, unscheduled 
clinic visits, ED visits, and hospitalizations.31 With the use 
of an asthma action plan, patients are empowered to prevent 
their symptoms from getting worse, monitor symptoms or 
peak expiratory flows to guide an appropriate response, and Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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take their prescribed controller and rescue medications. It is 
important to note that studies have shown that reviewing a 
patient’s asthma action plan at every visit can increase the 
patient’s medication adherence.32 Patients should bring their 
asthma action plans to every scheduled and unscheduled 
asthma-related visit. This will enhance continuity of care.
Five effective elements of asthma action plans include: 
(1) recommended doses and schedule of daily medications 
and how to adjust them in response to particular symptoms or 
peak flow measurements; (2) a record of the patient’s “best” 
peak flow measurement, as well as ranges of impairment, 
which can help patients recognize when control is being com-
promised; (3) warning signs and symptoms that indicate the 
need for closer monitoring or acute care; (4) emergency tele-
phone numbers for the health care provider, ED, rapid trans-
portation, and family or friends; and (5) list of triggers that 
may cause an asthma attack to inform the patient and others 
of triggers to avoid.
Anticipating and answering 
patients’ questions
As part of overall asthma management, NPs are well prepared 
to provide the education necessary to improve symptom 
control.16 The role of education extends to anticipating and 
answering patients’ questions about their degree of asthma 
control. The patient may want and need to address issues that 
can be resolved with information or a change in therapy. If the 
patient asks why his or her asthma is not controlled, the NP 
should explore possible reasons and ensure that patients know 
their asthma triggers and avoid environmental   exposures that 
worsen their asthma, such as allergens, irritants, and tobacco 
smoke.7 It is equally important to ensure that the patient is 
taking medication as prescribed. This includes the correct use 
of devices such as inhalers, spacers, and nebulizers, which 
should be demonstrated to the patient by the NP and then 
demonstrated by the patient to the NP.7 The patient should not 
be blamed if he or she is not taking medication as prescribed; 
rather, he or she should be made aware that many patients 
with asthma and other chronic diseases are nonadherent 
to therapy but that adherence is extremely important for 
  successful outcomes.33,34
Patients who are practicing trigger avoidance and are 
taking their medications as prescribed, yet still have uncon-
trolled asthma, may require a change in treatment. For 
example, patients with allergic asthma, who comprise more 
than half of individuals with asthma, may need a medica-
tion that addresses the allergic component of the disease.35 
If this is the case, these patients should be educated about 
the nature of their allergic triggers (Figure 5) and informed 
about avoidance measures and medications available for 
treatment.
Pharmacotherapy
Classes of asthma medications
NPs have many medication options available when treating 
their asthma patients. Medications for asthma consist of agents 
for long-term control and quick-relief rescue.7 Table 3 provides 
an overview of these medications and their mechanisms of 
action. Long-term control agents are used daily to achieve 
and maintain asthma control. The most effective agents in this 
class counteract the inflammation that underlies asthma.7 This 
class includes inhaled corticosteroids (ICSs), the cornerstone 
of treatment for persistent asthma.7,36 In contrast, quick-relief 
medications (the preferred among which are SABAs) treat 
Table 2 validated instruments for assessing asthma control25–27,29
Instrument Assessments Number of  
questions/items
Score interpretation
Asthma control questionnaire  
(ACQ)25,26
• Adequacy of asthma control 
• Change in asthma control
7 0 = totally controlled 
6 = severely uncontrolled
Asthma therapy assessment  
questionnaire (ATAQ)27
• Self-perceived asthma control 
• Missed school, work, or daily activities 
• Nighttime awakenings due to asthma symptoms 
• Use of quick-relief inhaler medications
4 0 = no control issues 
4 = 4 control issues
Asthma control test (ACT)29 • Productivity at work/school 
• Shortness of breath 
•   Nighttime/early morning awakenings  
due to symptoms
• Use of rescue medications 
• Self-rating of asthma control
5 Not specified – up to 
discretion of physicianJournal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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Table 3 Classes of asthma medications7,36–38,40
How used Class Example(s) of approved agents Mechanism of action
Long-term controllers iCSs beclomethasone  
budesonide  
fluticasone  
mometasone
Anti-inflammatory effects
immunomodulators omalizumab Anti-inflammatory effects
Leukotriene modifiers montelukast  
zileuton
Anti-inflammatory effects
LABAs salmeterol  
formoterol
Bronchodilation
Methylxanthines theophylline Mild/moderate bronchodilation 
Mild anti-inflammatory effects
Combined iCS/LABA fluticasone/salmeterol  
budesonide/formoterol
Anti-inflammatory effects 
Bronchodilation
Quick-relief/exacerbations Anticholinergics ipratropium bromide Bronchodilation
SABAs albuterol  
levalbuterol
Bronchodilation
Oral corticosteroids prednisone/prednisolone Anti-inflammatory effects
Abbreviations: iCSs, inhaled corticosteroids; LABAs, long-acting β2-agonists; SABAs, short-acting β2-agonists.
acute symptoms, and help prevent exercise-induced broncho-
constriction, and exacerbations.7 The anticholinergic agent 
ipratropium bromide and oral systemic corticosteroids are used 
in addition to SABAs for the rescue treatment of moderate to 
severe exacerbations.7 Unlike SABAs, long-acting β2-agonists 
(LABAs) have a duration of bronchodilatory action of at least 
12 hours and are used as controller agents in combination with 
ICSs (see safety discussion below).7,32,37,38
 Leukotrienes are the key proinflammatory mediators 
in asthma and the most powerful bronchoconstrictors 
found in humans to date.39 Leukotriene modifiers consist of 
5-lipoxygenase inhibitors (zileuton), which block cysteinyl 
leukotriene production, and leukotriene receptor antagonists 
(montelukast and zafirlukast), which block cysteinyl leukot-
rienes from binding to their primary receptor.7,40 Leukotriene 
receptor antagonist agents are alternative but not preferred 
therapy for the treatment of mild persistent asthma.7
The immunomodulator class currently consists solely of 
omalizumab, a monoclonal antibody that inhibits binding of 
immunoglobulin E (IgE) to its receptor on the surface of mast 
ε-switch
Release
of IgE
Plasma cell
Allergens
Allergic
inflammation:
eosinophils and
lymphocytes
Mast cells
basophils
Exacerbation
B lymphocyte
Allergic
mediators
Figure 5 Overview of the allergic cascade. ige (immunoglobulin e) is produced by the plasma cells, which are derived from B lymphocytes. The ige moves through 
the extracellular fluid and vasculature until it binds to a high-affinity receptor, primarily found on mast cells and basophils. Cross-linking of the membrane IgE results in 
degranulation of the cell with mediator release and the resultant symptoms of asthma.
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cells and basophils, thereby decreasing mediators of asthmatic 
inflammation and the allergic response.7,36   Omalizumab is 
indicated for adolescents and adults with moderate to severe 
persistent asthma inadequately controlled with ICS who 
have documented reactivity to a perennial aeroallergen.41 
  Omalizumab significantly reduced exacerbations in 2 random-
ized, double-blind, placebo-controlled, multicenter trials, each 
consisting of a 16-week stable steroid phase and a 12-week 
steroid reduction phase.42,43 Fewer patients with asthma exac-
erbations were observed with omalizumab versus placebo in 
the stable steroid phase of these 2 trials (14.6% vs 23.3% and 
12.8% vs 30.5%, respectively) as well as the steroid-reduction 
phase (21.3% vs 32.3% and 15.7% vs 29.8%, respectively).42,43 
In a separate study by Holgate et al,44 exacerbation rates in 
patients treated with omalizumab were 35%–45% lower than 
the rates observed in the patients treated with placebo, although 
these differences did not reach statistical significance.44
Safety concerns
inhaled corticosteroids
The NAEPP guidelines state that ICSs are generally well 
tolerated and safe when used at the recommended doses.7 
However, long-term use (.1 year) of high doses of ICSs, 
particularly if given in combination with frequent courses 
of oral corticosteroids, may be associated with the risk of 
cataracts or reduced bone mineral density.7
Long-acting β2-agonists
Clinical trial evidence of an increased risk of asthma-related 
deaths in patients treated with salmeterol, and an increased 
risk of severe asthma exacerbations leading to hospitalizations 
and deaths, led to the Food and Drug Administration (FDA) 
determination in February 2010 that a black box warning was 
warranted on the labeling for all LABAs used in asthma.32,45 
The FDA also recommended that these agents be used only 
for patients whose asthma is inadequately controlled with a 
long-term asthma control medication such as an ICS, or whose 
disease severity clearly warrants initiation of treatment with 
both an ICS and LABA, and that LABAs should be discontin-
ued (but ICSs continued) once asthma control is achieved.7,45 
This safety communication also added a contraindication for 
LABA use without concomitant treatment with an asthma 
controller medication such as an ICS.45
Omalizumab
An analysis of data from controlled studies with omali-
zumab showed that the incidence of anaphylaxis (reported 
by investigator) was rare (omalizumab 0.14%, control 
0.07%).46 A separate analysis of the postmarketing safety 
database, including an estimated exposure of 57,300 patients 
from June 2003 to December 2006, indicated 124 cases of 
anaphylaxis attributable to omalizumab (0.2%).47 The 
labeling for omalizumab includes a warning concerning 
this risk of anaphylaxis, and recommends that patients be 
observed closely after drug administration.41 The warning 
also stipulates that health care providers administering 
omalizumab be prepared to manage anaphylaxis, and inform 
patients of the signs and symptoms of the condition so that 
they can seek immediate medical care should symptoms 
occur.41
Malignant neoplasms were observed in 0.5% of omal-
izumab-treated patients compared with 0.2% of control 
patients in clinical studies of adults and adolescents (aged $ 
12 years) with asthma and other allergic disorders.46 The 
majority of malignant neoplasms were reported during the 
first 52 weeks of treatment and the impact of longer exposure 
to omalizumab is not known.46 Based on comparisons with 
the NIH Surveillance, Epidemiology and End Results (SEER) 
database, the incidence of malignancy in the omalizumab 
group was found to be similar to the incidence expected in 
the general population.46 In a separate analysis, an expert 
panel of oncologists concluded that the increased occurrence 
of malignancies observed in clinical trials was not due to 
omalizumab and that the malignancies occurred before the 
study began.48 Furthermore, of the 25 reported neoplasms, 
22 were found to be unrelated to the study drug and 3 were 
believed to have a remote relation to it.48
The patient with difficult-to-treat 
asthma: when to refer to a specialist
Some patients with asthma are beyond the scope of general 
  practice. The NAEPP guidelines recommend referral to a 
  specialist if the patient meets any of the following criteria: 
asthma is difficult to control or is persistent, the patient 
has needed more than 2 oral corticosteroid bursts per year, 
Table 4 Criteria for referring a patient with difficult-to-treat 
asthma to a specialist
Patients should be referred if they meet ANY of the criteria 
below:
• Asthma is difficult to control or is persistent
• .2 oral corticosteroid bursts per year are needed
• exacerbations have required hospitalization
•   Therapy at step 4 or higher is required to achieve adequate asthma 
control
• immunotherapy or therapy with omalizumab is being considered
• Additional testing is needed
Note: Reproduced from the National Heart Lung and Blood institute.7Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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  exacerbations have required hospitalization, therapy at step 
4 or higher is required to achieve adequate asthma control, 
immunotherapy or therapy with omalizumab is being con-
sidered, or additional testing is needed.7 Table 4 summarizes 
these criteria.
Conclusion
Many patients live with uncontrolled asthma, despite the 
availability of effective treatment options. NPs have a unique 
opportunity as frontline caregivers and patient educators to 
recognize and assess uncontrolled asthma as well as deter-
mine the steps necessary to help patients gain and maintain 
symptom control. With the implementation of the NAEPP 
guidelines, the role of NPs in asthma care will become 
particularly critical. NPs are ideally suited to the roles of 
primary purveyors of asthma education, promoters of patient 
partnerships for health care optimization, and providers of 
ongoing monitoring to ensure consistent achievement of 
therapeutic goals for asthma control.16
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